Biocardia reports 2024 business highlights and financial results

Sunnyvale, calif., march 26, 2025 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended december 31, 2024 and filed its annual report on form 10-k with the securities and exchange commission.
BCDA Ratings Summary
BCDA Quant Ranking